Bronchitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 86: Line 86:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''For severe disease'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''For severe disease'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amoxicillin-Clavulanate]] 875/125 mg po bid <br> 500/125 mg po q8h <br> 2000/125 mg po bid''''' <br>OR<br>▸''''' [[Azithromycin]] 500 mg po x 1 dose, then 250 mg q24h x 4 days <br> 500 mg po q24h x 3 days '''''  <br>OR<br> ▸'''''[[Clarithromycin]] extended release 1000 mg po q24h ''''' <br>OR<br> ▸'''''[[Cefaclor]] 500 mg po q8h or 500 mg extended release q12h '''''<br>OR<br> ▸ '''''[[Cefdinir]] 300 mg po q12h or 600 mg po q24h'''''<br>OR<br> ▸'''''[[Cefditoren]] 200 mg tabs—2 tabs bid '''''<br>OR<br> ▸'''''[[Cefpodoxime proxetil]] 200 mg po q12h'''''<br>OR<br> ▸'''''[[Cefprozil]] 500 mg po q12h'''''<br>OR<br> ▸'''''[[Ceftibuten]] 400 mg po q24h'''''<br>OR<br> ▸'''''[[Cefuroxime axetil]] 250 or 500 mg q12h'''''<br>OR<br> ▸'''''[[Levofloxacin]] 500 mg po q24h'''''<br>OR<br> ▸'''''[[Moxifloxacin]] 400 mg po q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amoxicillin-Clavulanate]] 875/125 mg po bid <br>OR<br>500/125 mg po q8h <br>OR<br> 2000/125 mg po bid''''' <br>OR<br>▸''''' [[Azithromycin]] 500 mg po x 1 dose, then 250 mg q24h x 4 days <br> 500 mg po q24h x 3 days '''''  <br>OR<br> ▸'''''[[Clarithromycin]] extended release 1000 mg po q24h ''''' <br>OR<br> ▸'''''[[Cefaclor]] 500 mg po q8h or 500 mg extended release q12h '''''<br>OR<br> ▸ '''''[[Cefdinir]] 300 mg po q12h or 600 mg po q24h'''''<br>OR<br> ▸'''''[[Cefditoren]] 200 mg tabs—2 tabs bid '''''<br>OR<br> ▸'''''[[Cefpodoxime proxetil]] 200 mg po q12h'''''<br>OR<br> ▸'''''[[Cefprozil]] 500 mg po q12h'''''<br>OR<br> ▸'''''[[Ceftibuten]] 400 mg po q24h'''''<br>OR<br> ▸'''''[[Cefuroxime axetil]] 250 or 500 mg q12h'''''<br>OR<br> ▸'''''[[Levofloxacin]] 500 mg po q24h'''''<br>OR<br> ▸'''''[[Moxifloxacin]] 400 mg po q24h'''''
|-
|-
|}
|}

Revision as of 17:46, 3 February 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Bronchitis Main page

Patient Information

Overview

Causes

Classification

Acute bronchitis
Chronic bronchitis

Differential Diagnosis

Overview

Bronchitis is usually caused by a viral agent. The treatment of bronchitis is usually symptomatic with analgesics, decongestants, cough suppressant (codeine or hydrocodone-containing preparations or inhaled corticosteroids). Use of antibiotics should be limited to conditions when a diagnosis with a definitive pathogen is there. Oseltamivir for influenza (during influenza epidemics), and azithromycin for atypical bacterias like mycoplasma, chlamydiae has been shown useful in clinical trials.

Medical Therapy

Acute Bronchitis

Symptomatic

Treatment for acute bronchitis is primarily symptomatic.

  • Non-steroidal anti-inflammatory drugs (NSAIDs) may be used to treat fever and sore throat.
  • Decongestants can be useful in patients with nasal congestion, and
  • Expectorants may be used to loosen mucus and increase expulsion of sputum.
  • Cough suppressants may be used if the cough interferes with sleep or is bothersome, although coughing may be useful in expelling sputum from the airways. Even with no treatment, most cases of acute bronchitis resolve quickly.

Antimicrobial Agent

  • Only about 5–10% of bronchitis cases are caused by a bacterial infection. Most cases of bronchitis are caused by a viral infection and are "self-limiting" and resolve themselves in a few weeks.[1]
  • Antimicrobial agents are not recommended in most cases of acute bronchitis. Various randomized controlled trials and systematic reviews have shown a decrease in symptoms by just a fraction of day with use of antibiotics when compared with placebo. These results though statistically significant are not clinically significant (as improvement by only a fraction of day). Antibiotic therapy did not help in a trial of patients who mainly had bronchitis.[2] About 15% had chronic obstructive lung disease and their results were not reported separately.[2]
  • However, treatment with antibiotics can be administered in cases with a definitive treatable pathogen is there. For e.g. treatment of influenza virus with oseltamivir decrease the duration of symptoms by approximately 1 day and result in an earlier return to normal activity Similarly, treatment of patients with pertussis is indicated to limit transmission when the therapy is initiated during the first week of symptoms. However, the symptoms are not less severe even with administration of these antibiotics.
  • Thus, in case of definitive diagnosis antibiotics can be used for:
  • Influenza
  • Atypical bacteria (Bordetella pertusis, mycoplasma pneumonia, chlamydiae pneumonia)
    • Azithromycin (Zithromax) 500mg on day 1 followed by 250mg from day 2-5.

Other Therapy

  • Various other treatments like beta 2 agonist, mucolytic agents, anti-tussive agent and corticosteroids have been used in different settings but no proven benefits have been shown in any of the clinical trials.

Chronic Bronchitis Treatment

Chronic bronchitis is treated symptomatically. Inflammation and edema of the respiratory epithelium may be reduced with inhaled corticosteroids. Wheezing and shortness of breath can be treated by reducing bronchospasm (reversible narrowing of smaller bronchi due to constriction of the smooth muscle) with bronchodilators such as inhaled β-Adrenergic agonists (e.g., salbutamol) and inhaled anticholinergics (e.g., ipratropium bromide). Hypoxemia, too little oxygen in the blood, can be treated with supplemental oxygen. However, oxygen supplementation can result in decreased respiratory drive, leading to increased blood levels of carbon dioxide and subsequent respiratory acidosis.

The most effective method of preventing chronic bronchitis and other forms of COPD is to avoid smoking cigarettes and other forms of tobacco.

On pulmonary tests, a bronchitic (bronchitis) may present a decreased FEV1 and FEV1/FVC. However, unlike the other common obstructive disorders, asthma and emphysema, bronchitis rarely causes a high residual volume. This is because the air flow obstruction found in bronchitis is due to increased resistance, which, in general, does not cause the airways to collapse prematurely and trap air in the lungs.[citation needed]

Antibiotics

In most cases, acute bronchitis is caused by viruses, not bacteria and it will go away on its own without antibiotics. To treat acute bronchitis that appears to be caused by a bacterial infection, or as a precaution, antibiotics may be given.[3]

If antibiotics are used, a meta-analysis found that "amoxicillin/clavulanic acid, macrolides, second-generation or third-generation cephalosporins, and quinolones" may be more effective.[4]


Antibiotic therapy

Following are the guidelines to treat cystic fibrosis based on the age, condition associated and microbial agent.[5][6][7][8][9]



Bronchitis

  ▸  Chronic with Acute Exacerbation

  ▸  Bronchiectasis

  ▸  Pertussis

Chronic with Acute Exacerbation
Preferred Regimen
For mild or moderate disease
Amoxicillin 500 mg po tid
OR
Doxycycline 100 mg po bid
OR
TMP-SMX 1 DS tab po bid
For severe disease
Amoxicillin-Clavulanate 875/125 mg po bid
OR
500/125 mg po q8h
OR
2000/125 mg po bid

OR
Azithromycin 500 mg po x 1 dose, then 250 mg q24h x 4 days
500 mg po q24h x 3 days

OR
Clarithromycin extended release 1000 mg po q24h
OR
Cefaclor 500 mg po q8h or 500 mg extended release q12h
OR
Cefdinir 300 mg po q12h or 600 mg po q24h
OR
Cefditoren 200 mg tabs—2 tabs bid
OR
Cefpodoxime proxetil 200 mg po q12h
OR
Cefprozil 500 mg po q12h
OR
Ceftibuten 400 mg po q24h
OR
Cefuroxime axetil 250 or 500 mg q12h
OR
Levofloxacin 500 mg po q24h
OR
Moxifloxacin 400 mg po q24h
Bronchiectasis
Preferred Regimen
Levofloxacin 500 mg po q24h for 14 days
OR
Moxifloxacin 400 mg po q24h for 14 days
Pertussis
Preferred Regimen
Infant (age < 1 month)
Azithromycin 10 mg/kg/d for 5 days
OR
TMP-SMX (8/40 mg/kg/day) in two divided doses x 14 days
Infant 1-5 mo of age
Azithromycin 10 mg/kg/d for 5 days
OR
TMP-SMX 40 mg/kg/d in 4 divided doses for 14 days
Infant (age > 6 months)
Azithromycin children: 10 mg/kg on day 1, then 5 mg/kg/d for days 2-5 (max dose 500 mg
OR
Erythromycin children: 40 mg/kg/d in 4 divided doses for 14 days (max dose 2000 mg/day)
Adult
Azithromycin 500 mg day 1, then 250 mg days 2-5
OR
Erythromycin 500 mg 4 times daily x 14 days
Alternate Regimen
Infant 1-5 mo of age
Clarithromycin 15 mg/kg/d in two divided doses x 7 days
OR
TMP-SMX CONTRAINDICATED for age < 2 months
(8/40 mg/kg/day) in two divided doses x 14 days
Infant (age > 6 months)
Clarithromycin 15 mg/kg/d in two divided doses (max dose 1 gm/day) x 7 days
OR
TMP-SMX 8/40 mg/kg/day in two divided doses x 14 days)
Adult
Clarithromycin 500 mg 2 x/day x 7 days
OR
TMP-SMX 320/1600 mg/day in two divided doses x 14 days
' = Recommended agent ; Clarithromycin and TMP-SMX are contraindicated in children below 6 mths and 2 mths respectively

Smoking Cessation

To help the bronchial tree heal faster and not make bronchitis worse, smokers should completely quit smoking. [10]

References

  1. Hueston WJ (1997). "Antibiotics: neither cost effective nor 'cough' effective". The Journal of Family Practice. 44 (3): 261–5. PMID 9071245. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  2. 2.0 2.1 Little P, Stuart B, Moore M, Coenen S, Butler CC, Godycki-Cwirko M; et al. (2012). "Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial". Lancet Infect Dis. doi:10.1016/S1473-3099(12)70300-6. PMID 23265995.
  3. The Merck Manual of Medical Information: Bronchitis. February 2003. Accessed 20 March 2007.
  4. Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME (2007). "Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials to Joe Fo Sho". Chest. 132 (2): 447–55. doi:10.1378/chest.07-0149. PMID 17573508.
  5. Rothberg, MB.; Pekow, PS.; Lahti, M.; Brody, O.; Skiest, DJ.; Lindenauer, PK. (2010). "Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease". JAMA. 303 (20): 2035–42. doi:10.1001/jama.2010.672. PMID 20501925. Unknown parameter |month= ignored (help)
  6. Zaidi, N.; Nawab, Q. (2012). "Antibiotic prevention of acute exacerbations of COPD". N Engl J Med. 367 (19): 1864–5, author reply 1867. doi:10.1056/NEJMc1210335#SA1. PMID 23134397. Unknown parameter |month= ignored (help)
  7. Pasteur, MC.; Bilton, D.; Hill, AT.; Pasteur, MC.; Bilton, D.; Hill, AT.; Stockley, RA.; Wilson, R.; Pasteur, MC. (2010). "British Thoracic Society guideline for non-CF bronchiectasis". Thorax. 65 Suppl 1: i1–58. doi:10.1136/thx.2010.136119. PMID 20627931. Unknown parameter |month= ignored (help)
  8. "CDC - Pertussis: Guidelines for Control of Outbreaks".
  9. Tiwari, T.; Murphy, TV.; Moran, J. (2005). "Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines". MMWR Recomm Rep. 54 (RR-14): 1–16. PMID 16340941. Unknown parameter |month= ignored (help)
  10. The American Academy of Family Physicians: Acute Bronchitis. January 2006. Accessed 20 March 2007.


Template:WikiDoc Sources